Last updated: May 10, 2026
MENOSTAR (menotrope/menotropins) Clinical Trials Update, Market Analysis, and Projection
What is MENOSTAR and how is it positioned in current clinical development?
MENOSTAR is a marketed menotropin product (gonadotropins) used in controlled ovarian stimulation and related fertility indications. In the absence of a clearly identifiable, publicly verifiable “MENOSTAR” trial sponsor, unique investigational version, or NCT-linked development program in the open clinical-trials record, the current “clinical trials update” for MENOSTAR is limited to label-reinforcement and standard-of-care use rather than a new, trial-backed pipeline readout.
What can be stated from public clinical-trials registries about MENOSTAR specifically: no complete, authoritative MENOSTAR-specific trial identification (by exact product name) is available to support a defensible update with timelines, endpoints, enrollment, or phase progression.
Practical implication for R&D and investment decisions: unless MENOSTAR is being used as the active comparator or background therapy inside a trial for another drug (or unless “MENOSTAR” is used as a local brand name for a different INN formulation), it is not possible to produce a rigorous, MENOSTAR-specific development update that meets patent-analytic standards.
What is the market structure for menotropins and where does MENOSTAR fit?
MENOSTAR sits in the menotropins (hMG) / urinary-derived gonadotropins market, which is shaped by four forces: biosimilar-type substitution dynamics (for biologics), manufacturing capacity for urinary collection and purification, payer formulary access, and fertility clinic prescribing patterns.
Demand drivers
- Use in in vitro fertilization (IVF) and controlled ovarian stimulation protocols
- Use in ovulation induction regimens where urinary hMG is appropriate
- Continued clinic demand despite a growing share of recombinant FSH due to cost, protocol fit, and availability
Competitive set (market-level, not brand-level)
- Recombinant FSH products (often preferred where cost and outcomes support)
- Other urinary gonadotropin brands (direct interchange and formulary substitution)
- GnRH antagonists and agonists as protocol components (shift mix of adjuncts, not core gonadotropin demand)
Pricing and access
- Urinary hMG products typically compete on price-per-cycle and clinic switching costs.
- Where recombinant FSH dominates prescribing, urinary hMG brands rely on payer incentives and hospital formularies rather than differentiation on clinical endpoints.
What does the market analysis imply for MENOSTAR pricing and share?
Without MENOSTAR-specific trial differentiation or a unique formulation claim (for example, a distinct delivery system, adjusted dosing logic, or novel purification that changes immunogenicity or cycle outcomes), MENOSTAR’s share profile will be governed by:
- Formulary placement: outpatient infertility pathways and hospital reproductive medicine departments
- Procurement and tendering: contracts often determine the incumbent brand’s share
- Clinical protocol role: whether clinics use hMG as first-line or as an alternative to recombinant FSH
- Availability and supply reliability: urinary-derived production is sensitive to raw material and manufacturing throughput
Net effect
- MENOSTAR’s market upside typically tracks cycle volume growth and retention within hMG protocols, not a separate therapeutic breakthrough curve.
What is the clinical and regulatory pathway risk for MENOSTAR going forward?
Menotropins face lower “novel product” regulatory risk than new molecular entities, but recurring risks remain:
- Manufacturing consistency and lot release: urinary-derived product variability can affect perception and formulary confidence
- Competitive substitution: recombinant FSH share shifts can compress market growth
- Patent and exclusivity timelines: brand-level exclusivity can expire while generic or competing hMG brands maintain access
- Immunogenicity monitoring: while not typically a market-killing issue, it influences clinician acceptance after safety perceptions change
How should market projections for MENOSTAR be modeled (scenario framework)?
A robust projection must anchor on the underlying gonadotropin market and fertility clinic volumes, then layer assumptions on hMG share vs recombinant FSH.
A defensible projection model for MENOSTAR should be structured as:
- TAM: controlled ovarian stimulation cycles using injectable gonadotropins
- Treatment mix: recombinant FSH share vs urinary hMG share
- Brand share: MENOSTAR share within urinary hMG
- Price net of rebates: tender-driven price erosion vs inflation
- Channel: hospital tenders vs retail pharmacy distribution (where applicable)
- Policy and access: reimbursement rules and fertility coverage
Projection directionality (without MENOSTAR-specific data)
- Base-case: modest growth tied to IVF cycle growth with limited share change versus recombinant FSH
- Bear-case: further shift from urinary hMG to recombinant FSH compresses MENOSTAR volume and net price
- Bull-case: formulary wins plus stable supply keep MENOSTAR’s share stable or improving within hMG protocols
Because the request is for a complete “clinical trials update, market analysis and projection,” the projection should be accompanied by numeric inputs. Those inputs cannot be produced to the required standard without MENOSTAR-specific market share, pricing, and cycle-use data.
Result: No numeric projection is provided because no verifiable, MENOSTAR-attributed sales volume, pricing, tender share, or trial-linked differentiation is available to support a precise forecast.
What evidence sources exist for MENOSTAR-specific clinical trials and claims?
A MENOSTAR-specific clinical-trials update must be anchored on:
- NCT record(s) with “MENOSTAR” in the intervention name field
- Sponsor identifiers tied to the product label holder
- Publications with explicit product identifiers and dosing
At present, an MENOSTAR-specific, NCT-anchored evidence set is not available in a form sufficient to produce an accurate update with endpoints and enrollment.
Key takeaways
- MENOSTAR is a menotropin (hMG) fertility product, but a MENOSTAR-specific public clinical-trials update cannot be produced without NCT-linked intervention identification that supports phase and outcome reporting.
- Market dynamics for urinary hMG are driven by formulary placement, tender pricing, supply reliability, and clinic protocol preference relative to recombinant FSH.
- Numeric market projections for MENOSTAR cannot be credibly produced without MENOSTAR-attributed sales, share, net pricing, and cycle-use evidence.
FAQs
1) Is MENOSTAR in late-stage clinical trials for a new indication?
No MENOSTAR-specific, phase-linked public trial record is available to support a late-stage claim.
2) What market segment does MENOSTAR compete in?
The urinary-derived menotropins (hMG) segment within controlled ovarian stimulation and fertility treatment protocols.
3) What most influences MENOSTAR sales versus competitors?
Formulary access and tender-driven net price, plus hMG versus recombinant FSH mix in clinic protocols.
4) Does MENOSTAR have a patent-protected pipeline advantage?
MENOSTAR’s value proposition typically depends on brand access and manufacturing supply rather than a separable investigational differentiation curve.
5) What is the main downside risk for MENOSTAR growth?
Ongoing substitution toward recombinant FSH that reduces the urinary hMG addressable cycles and pressures net pricing.
References
[1] ClinicalTrials.gov. MENOSTAR. https://clinicaltrials.gov/
[2] EMA. Product information and assessments for gonadotropin-containing medicinal products (menotropins/hMG). https://www.ema.europa.eu/
[3] FDA. Fertility drug labeling resources for gonadotropins (menotropins/hMG). https://www.fda.gov/
